Neumora Therapeutics Stock Forecast

NMRA's stock price has decreased by -62.97% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

According to 9 analysts polled by S&P Global, Neumora Therapeutics stock has a consensus rating of "Buy" and an average price target of $6.14. The average 1-year stock price forecast is 806.14% higher than the current stock price, while the lowest is $3.00 (+342.74%) and the highest is $14 (+1,966.12%).

Price Target: $6.14 (+806.14%)

Analyst Consensus: Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$3.00	$6.14	$5.00	$14
Change	+342.74%	+806.14%	+637.90%	+1966.1%

* Price targets were last updated on Aug 24, 2026.

Analyst Ratings

The average analyst rating for Neumora Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart

Rating	Mar '26	Apr '26	May '26	Jun '26	Jul '26	Aug '26
Strong Buy	5	5	5	5	5	5
Buy	2	2	2	2	2	2
Hold	1	1	1	1	1	1
Sell	1	1	1	1	1	1
Strong Sell	0	0	0	0	0	0
Total	9	9	9	9	9	9

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Douglas Tsao H.C. Wainwright	H.C. Wainwright	Buy Reiterates $7	Buy	Reiterates	$7	+933.06%	Aug 24, 2026
Graig Suvannavejh Mizuho Securities	Mizuho Securities	Buy Reiterates $4	Buy	Reiterates	$4	+490.32%	Aug 17, 2026
Ami Fadia Needham	Needham	Buy Reiterates $5	Buy	Reiterates	$5	+637.90%	Aug 14, 2026
Myles Minter William Blair	William Blair	Buy Reiterates n/a	Buy	Reiterates	n/a	n/a	Aug 14, 2026
Brian Abrahams RBC Capital	RBC Capital	Buy Maintains $5	Buy	Maintains	$5	+637.90%	Aug 14, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

-0.87

from -1.45

EPS Next Year

-0.67

from -0.87

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	-	-	-
Operating Income	-80.32M	-122.87M	-188.19M	-263.46M	-236.16M	-165.87M
Net Income	-237.31M	-130.90M	-235.93M	-243.79M	-236.93M	-168.58M
EPS	-	-	-	-	-1.45	-0.87
Free Cash Flow	-	-	-	-	-206.44M	-151.20M
No. Analysts	-	-	-	-	-	9

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	n/a
Avg	n/a
Low	n/a

Revenue Growth

Chart

Revenue Growth	2027	2028
High	-
Avg	-
Low	-

EPS Forecast

Chart

EPS	2026	2027	2028
High	-0.65
Avg	-0.87
Low	-0.94

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-